Update on alisporivir in treatment of viral hepatitis C
- PMID: 22316207
- DOI: 10.1517/13543784.2012.658641
Update on alisporivir in treatment of viral hepatitis C
Abstract
Introduction: There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals (DAA) and host-targeting antivirals (HTA). Cyclophilin inhibitor alisporivir (ALV) , previously known as Debio-025 is the most advanced HTA in development.
Areas covered: Experimental and clinical studies demonstrated that ALV has high genetic barrier and no cross-resistance to DAA. Pharmacokinetic studies showed a profile suitable for once-daily administration. Phase I and II studies confirmed strong HCV suppression and that addition of ALV to pegylated IFNα (PegIFNα) and ribavirin (RBV) can improve their efficacy significantly. ALV was well tolerated and prevalence of the most frequent clinical and laboratory adverse events was similar to PegIFNα/RBV. Hyperbilirubinemia was the only significant adverse event related to ALV, but it was transient, reversible and not associated with hepatotoxicity or cholestasis.
Expert opinion: ALV is pangenotypic, with once-daily administration and safe, therefore medication can be easy and flexible. There is still a need of data in difficult-to-treat populations and genetic studies allowing selection of possible non-responders. Registration of ALV for IFN-based treatment is expected within 3 years, but ALV is also a good candidate for IFN-sparing combinations with DAA.
Similar articles
-
Efficacy and safety of alisporivir for the treatment of hepatitis C infection.Expert Opin Pharmacother. 2019 Mar;20(4):379-384. doi: 10.1080/14656566.2018.1560424. Epub 2018 Dec 21. Expert Opin Pharmacother. 2019. PMID: 30576256 Review.
-
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14. Epub 2014 Mar 31. Antimicrob Agents Chemother. 2014. PMID: 24687498 Free PMC article.
-
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.Hepatology. 2014 May;59(5):1706-14. doi: 10.1002/hep.26989. Epub 2014 Apr 1. Hepatology. 2014. PMID: 24375768 Clinical Trial.
-
Profile of alisporivir and its potential in the treatment of hepatitis C.Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15. Drug Des Devel Ther. 2013. PMID: 23440335 Free PMC article. Review.
-
Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.Curr Opin Investig Drugs. 2010 Feb;11(2):213-24. Curr Opin Investig Drugs. 2010. PMID: 20112171 Review.
Cited by
-
The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity.Viruses. 2023 Oct 17;15(10):2099. doi: 10.3390/v15102099. Viruses. 2023. PMID: 37896876 Free PMC article.
-
Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus.Viruses. 2023 Apr 17;15(4):981. doi: 10.3390/v15040981. Viruses. 2023. PMID: 37112961 Free PMC article.
-
Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents.Drug Discov Today. 2022 Jul;27(7):1895-1912. doi: 10.1016/j.drudis.2022.05.016. Epub 2022 May 21. Drug Discov Today. 2022. PMID: 35609743 Free PMC article. Review.
-
Host Factors in Coronavirus Replication.Curr Top Microbiol Immunol. 2018;419:1-42. doi: 10.1007/82_2017_25. Curr Top Microbiol Immunol. 2018. PMID: 28643204 Free PMC article. Review.
-
Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.Virus Res. 2017 Jan 15;228:7-13. doi: 10.1016/j.virusres.2016.11.011. Epub 2016 Nov 10. Virus Res. 2017. PMID: 27840112 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical